RLMD — RELMADA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1553643 ·
Last close
$6.37
Market Cap
$668.15M
52W High
$8.00
52W Low
$5.64
ADV30
1,101,509
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -19,461,754 | -19,051,956 | 235,362,794 | 9,776,400 | 16,630,217 |
| Dec 2025 | 0 | — | -20,333,112 | -19,867,760 | 94,003,471 | 3,496,540 | 7,491,458 |
| Sep 2025 | 0 | — | -10,327,346 | -10,091,496 | 14,876,244 | 1,384,484 | 5,410,705 |
| Jun 2025 | 0 | — | -10,221,306 | -9,866,442 | 21,116,144 | 1,353,351 | 5,166,663 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-42,787,443
Investing CF
$-198,725,016
Financing CF
$250,139,153
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.40
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-717,319,154
Inventory
—
Receivables
—
ST Investments
$224,186,743
EBIT TTM
$-60,343,518
Pretax Income TTM
$-58,877,654
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,100,200 | -57,385,163 | 94,003,471 | 7,491,458 | — | -45,786,988 |
| Dec 2024 | 0 | -83,891,036 | -79,979,354 | 45,817,818 | 10,295,857 | — | -51,755,798 |
| Dec 2023 | 0 | -103,702,293 | -98,791,746 | 97,552,042 | 12,194,800 | — | -51,659,206 |
| Dec 2022 | 0 | -161,249,076 | -157,043,823 | 152,905,179 | 12,468,877 | — | -103,801,617 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.41
Max Pain — expiry 2026-06-18
max pain strike: $5.00 · spot: $6.48 · call oi: 3,645 · put oi: 506
Expected Move to 2026-06-18:
±$1.12
(17.36%) —
implied range
$5.36 –
$7.61
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANL | Adlai Nortye Ltd. | $665.46M | $11.33 | — |
| CRMD | CorMedix Inc. | $673.90M | $8.59 | — |
| CTMX | CytomX Therapeutics, Inc. | $661.82M | $3.04 | — |
| OMER | OMEROS CORP | $675.26M | $9.33 | — |
| CLYM | Climb Bio, Inc. | $657.95M | $11.49 | — |
News headlines (Yahoo Finance, 1h cache)
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
2026-06-11 11:00 · Yahoo
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
2026-05-28 11:00 · Yahoo
Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...
2026-05-13 05:02 · Yahoo
Relmada Therapeutics Q1 Earnings Call Highlights
2026-05-13 02:06 · Yahoo
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 20:05 · Yahoo
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
2026-05-06 11:00 · Yahoo
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
2026-05-05 11:00 · Yahoo
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
2026-04-13 13:55 · Yahoo
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
2026-04-06 15:10 · Yahoo
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
2026-04-02 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.